Vasculite
Revisado por Dr Hayley Willacy, FRCGP Última atualização por Dr Colin Tidy, MRCGPÚltima atualização 19 de maio de 2022
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Versão em Áudio
- Adicionar às fontes preferidas no Google
Profissionais de Saúde
Os artigos de Referência Profissional são projetados para uso por profissionais de saúde. Eles são escritos por médicos do Reino Unido e baseados em evidências de pesquisa, diretrizes do Reino Unido e da Europa. Você pode encontrar um dos nossos artigos de saúde mais útil.
What is vasculitis?
Vasculitis is a term used to describe a series of conditions in which there is inflammation of the blood vessels.
Vasculitis can be primary (occurring on its own), or secondary (as a result of infection, or in association with another condition such as rheumatoid arthritis).
The effects might be transient or result in longer-term damage to the vasculature.
How common is vasculitis? (Epidemiology)
Vasculitis is rare. About 14,000 new cases are diagnosed in the UK each year.1 A UK general practice study found that the most common type - polymyalgia rheumatica (PR) - had an estimated cumulative prevalence (the number of people who had ever had the disease over a given period of time) of 2.27%. The corresponding figure for the next most common - giant cell arteritis (GCA) - was 0.41%.2
Vasculitis causes (aetiology)
Idiopathic (45-55%).
Infection (15-20%) - eg, Henoch-Schönlein purpura, septic vasculitis, upper respiratory tract flares of granulomatosis with polyangiitis (GPA), polyarteritis nodosa (PAN).
Inflammatory disease (15-20%) - eg, systemic lupus erythematosus (SLE), rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Drug-induced (10-15%) - eg, sulfonamides, beta-lactams, quinolones, non-steroidal anti-inflammatory drugs (NSAIDs), oral contraceptives, thiazides, anti-influenza vaccines. Chemicals such as insecticides and petroleum products.
Neoplastic (<5%) - eg, as a result of a paraproteinaemia or lymphoproliferative disorder.
Classificação
Many attempts have been made to classify this group of diseases and several classifications are in existence. The Chapel Hill Consensus Conference (CHCC) broadly classified the causes of vasculitis into infective and non-infective and then went on to classify the non-infective causes further.3
Infective causes are considered as those where there is direct invasion by pathogens into the vascular wall, resulting in inflammation. Examples include rickettsial vasculitis, syphilitic aortitis and aspergillus arteritis.
For non-infective causes, the CHCC classified vasculitis into:
Large-vessel (eg, GCA) | Single-organ (eg, isolated aortitis) |
Medium-vessel (eg, Kawasaki disease) | Systemic disease-associated (eg, rheumatoid) |
Small-vessel (eg, immune complex) | Probably associated (eg, hepatitis B, hepatitis C) |
Variable-vessel (eg, Behçet's disease) |
|
The CHCC classification applies to vasculitides (the pleural of vasculitis) in which antineutrophil cytoplasmic antibody (ANCA) is present in the blood. This is known as ANCA-associated vasculitis (AAV).
The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions:4
Granulomatosis with polyangiitis (GPA - formerly known as Wegener's granulomatosis).
Microscopic polyangiitis (MPA).
Eosinophilic granulomatosis with polyangiitis (EGPA - previously known as Churg-Strauss syndrome).
Non-AAV usually occurs in conditions in which immune complex deposition occurs, (eg, Henoch-Schönlein purpura) or pan-neoplastic phenomena.5
Localised, single-organ vasculitides encompass a group of rare conditions in which there is no evidence of concomitant systemic vasculitis.6
Vasculitis symptoms
Vasculitis can affect any system, producing a wide range of symptoms. Although unspecific symptoms such as arthralgia and lethargy may be present for some time, frequently the first noticeable sign of a vasculitis will be as a skin lesion and will therefore present as such.
| Small-vessel vasculitis (Sometimes referred to as hypersensitivity vasculitis or cutaneous leukocytoclastic vasculitis (LCV)) | Medium-sized vessel vasculitis | Large-vessel vasculitis (ie aorta and major branches) |
Apresentação | Palpable purpura 1-3 mm (may join to form plaques ± ulcer) Tiny papules Hemorragias em estilhaço Urticária Vesicles Livedo reticularis (rare) | Úlceras Digital infarcts Nodules Livedo reticularis Papulo-necrotic lesions Hipertensão | End-organ ischaemia (eg, TIA/CVE) Hipertensão Aneurismas Dissection ± haemorrhage or rupture |
Diagnóstico diferencial | Púrpura de Henoch-Schönlein Cryoglobulinaemic vasculitis - idiopathic, hepatitis C Drug hypersensitivity reactions Infections (eg, beta-haemolytic streptococcus, viral hepatitis, HIV) Collagen vascular disease (eg, rheumatoid arthritis, Sjögren's syndrome, SLE) Doença inflamatória intestinal Neoplastic Causes of larger-vessel vasculitis (uncommon) | GPA vasculitis síndrome de Churg-Strauss Poliarterite nodosa doença de Kawasaki GCA Behçet's disease, Artrite reumatoide Infections (eg, tuberculosis) Erythema induratum (of Bazin) | doença de Kawasaki Doença de Behçet Artrite reumatoide Syphilis and tuberculosis Aorta, particularly GCA and |
Diagnosis of the skin lesion can provide information as to what calibre of vessel may be involved, potential diagnosis and where else in the body evidence of vasculitis should be sought.7 8
Full history should be taken, particularly with respect to:
Length of symptoms/signs.
Recent illness.
Recent exposure to drugs, vaccines and chemicals.
Other symptoms - eg, arthralgia, cough, ENT symptoms, numbness and paraesthesia.
Detailed review of all systems.
In view of the systemic nature of many vasculitic diseases, a complete physical examination should be carried out, including CNS and ENT examination.
Investigações
Investigations should be tailored to the possible cause. For all patients suspected of having a vasculitic lesion, consider:
Hemograma completo e contagem diferencial de células.
U&Es.
Testes de função hepática.
Inflammatory markers.
Urine culture, microscopy.
Urine dip test for glucose, protein and blood.
Hepatitis serology (types B and C are associated with PAN and mixed cryoglobulinaemia respectively).
Crioglobulinas.
Complement levels.
Rheumatoid factor.
Radiografia de tórax.
Also consider:
Echocardiogram and blood cultures if there is cardiac murmur present.
Antinuclear antibodies (ANAs) if there is medium-sized vessel involvement and any suggestion of connective tissue disease.
Skin biopsy taken during the acute stage.
Imaging - the use of imaging is a relatively new approach but MRI and colour Doppler ultrasonography both have potential in diagnosis of large-vessel vasculitis.9
Diagnóstico diferencial
There are several other conditions which may mimic cutaneous vasculitis and these must be considered when arriving at a diagnosis. Some of the more common ones include:
Trauma.
Pigmented lesions.
Púrpura (eg, due to low platelet count).
Vasculitis treatment and management
The treatment will vary considerably according to the underlying cause and the severity of symptoms and their duration. It may include:
Avoiding the precipitating factor, such as drugs or chemicals.
In general, corticosteroids are administered to control acute symptoms and laboratory evidence of systemic inflammation. After control is achieved, attempts may be made to taper dosing over a month.
Options such as immunosuppression with cyclophosphamide, azathioprine, methotrexate or tumour necrosis factor blockade may be used.
For ANCA-associated vasculitis, European guidelines recommend the use of mycophenolate mofetil.8
Use of plasmapheresis or intravenous immunoglobulin are options for refractory vasculitis.
There is increasing evidence for biological agents in vasculitis.10
Morbidity due to cumulative corticosteroid dose (as well as toxicity from immunosuppression) must be weighed in the long-term plan of care.
Cirúrgico
Occasionally, surgery might be indicated. The aims of this depend on the area affected but may be to open up or divert blood flow around an area of blockage, to take a sample (biopsy) or to repair an area of organ damage.
Exemplos incluem:
Stenting of stenotic vessels, which is increasingly used. Balloon dilatation has also been used to improve renovascular flow.
Patients with GPA may develop subglottic stenosis, which is amenable to balloon dilatation.
Acompanhamento
ESR may be used as a marker of disease activity.
Patients with elevated cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA) titres may have normal levels during periods of disease control and increasing ones with disease activity.
Prognóstico11
This is related to the degree of end-organ involvement.
The prognosis of ANCA-associated vasculitis has been transformed in recent years. Once it was a set of invariably acute and fatal conditions, but these disorders are currently considered to be chronic diseases. This change is largely attributable to earlier diagnosis and the use of immunotherapeutics. However, patients still experience premature mortality, relapse, comorbid ill health and poor quality of life.
Complicações
Complications are varied and are dependent on the underlying cause, size of vessel and organs affected. They may include:
Renal insufficiency.
Digital gangrene.
Pulmonary haemorrhage.
CNS infarction.
Arterial or venous thrombosis.
Subglottic stenosis.
Atualizações exclusivas para profissionais de saúde
Mantenha-se informado com as últimas atualizações clínicas, insights profissionais e orientações baseadas em evidências. O boletim informativo Patient Pro seleciona conteúdo essencial para profissionais de saúde—entregue diretamente na sua caixa de entrada.
Ao se inscrever, você aceita nossos Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.
Leitura adicional e referências
- Vasculite cutânea; DermNet NZ
- Brogan P, Eleftheriou D; Atualização sobre vasculite: fisiopatologia e biomarcadores. Pediatr Nephrol. 2018 fev;33(2):187-198. doi: 10.1007/s00467-017-3597-4. Epub 2017 8 de ago.
- Torp CK, Bruner M, Keller KK, et al; Vasculitis therapy refines vasculitis mechanistic classification. Autoimmun Rev. 2021 Jun;20(6):102829. doi: 10.1016/j.autrev.2021.102829. Epub 2021 Apr 16.
- Guggenberger KV, Bley TA; Imaging in Vasculitis. Curr Rheumatol Rep. 2020 Jun 19;22(8):34. doi: 10.1007/s11926-020-00915-6.
- Watts R et al; Rheumatology Volume 53, Issue suppl 1Pp. i187, 2016.
- Yates M, Graham K, Watts RA, et al; The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskelet Disord. 2016 Jul 15;17:285. doi: 10.1186/s12891-016-1127-3.
- Jennette JC, Falk RJ, Bacon PA, et al; 2012 revisão da Nomenclatura de Vasculites da Conferência de Consenso Internacional de Chapel Hill. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.
- Yates M, Watts R; ANCA-associated vasculitis. Clin Med (Lond). 2017 Feb;17(1):60-64. doi: 10.7861/clinmedicine.17-1-60.
- McKinney EF, Willcocks LC, Broecker V, et al; The immunopathology of ANCA-associated vasculitis. Semin Immunopathol. 2014 Jul;36(4):461-78. doi: 10.1007/s00281-014-0436-6. Epub 2014 Jul 24.
- Martins-Martinho J, Dourado E, Khmelinskii N, et al; Localized Forms of Vasculitis. Curr Rheumatol Rep. 2021 Jul 1;23(7):49. doi: 10.1007/s11926-021-01012-y.
- Kluger N, Frances C; Cutaneous vasculitis and their differential diagnoses. Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S124-38.
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis; Liga Europeia Contra o Reumatismo (2016)
- Miller A, Chan M, Wiik A, et al; An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol. 2010 May;160(2):143-60. doi: 10.1111/j.1365-2249.2009.04078.x. Epub 2010 Jan 12.
- Chen KR, Carlson JA; Abordagem clínica da vasculite cutânea. Am J Clin Dermatol. 2008;9(2):71-92.
- Basu N, Karabayas M, Pusey C; Prognosis and future developments in vasculitis. Best Pract Res Clin Rheumatol. 2018 Feb;32(1):148-165. doi: 10.1016/j.berh.2018.08.011. Epub 2018 Sep 22.
Sobre o autorVer biografia completa

Dr Colin Tidy, MRCGP
Médico Generalista, Autor Médico
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy é um médico do NHS, baseado em Oxfordshire.
Sobre o revisorVer biografia completa

Dr Hayley Willacy, FRCGP
Médico Generalista, Autor Médico
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
A Dra. Hayley Willacy era uma médica do NHS atuando no noroeste da Inglaterra, que se aposentou da prática clínica em 2022 após 30 anos.
Histórico do artigo
As informações nesta página são escritas e revisadas por clínicos qualificados.
Artigo também disponível em Inglês, Alemão, Espanhol, Francês, Italiano, Português, Hindi, Hebraico, Árabe, e Sueco.
Próxima revisão agendada: 18 de maio de 2027
19 de maio de 2022 | Última versão

Pergunte, compartilhe, conecte-se.
Navegue por discussões, faça perguntas e compartilhe experiências em centenas de tópicos de saúde.

Sentindo-se mal?
Avalie seus sintomas online gratuitamente
Mais em dermatologia
- Ceratose actínica
- Verrugas anogenitais
- Infecção por coxsackievirus
- Foliculite
- Psoríase pustulosa generalizada
- Gota
- Nevo em halo
- Vírus do herpes
- Hiperidrose
- Sarampo
- Melasma
- Infecções cutâneas por micobactérias
- Necrobiose lipoídica
- Herpes simples oral
- Pitiríase rósea
- Disidrose
- Piolhos pubianos e corporais
- Erupções purpúricas
- Técnicas de biópsia de pele na prática geral
- Eczema varicoso